<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39427297</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1600-0897</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>American journal of reproductive immunology (New York, N.Y. : 1989)</Title><ISOAbbreviation>Am J Reprod Immunol</ISOAbbreviation></Journal><ArticleTitle>Hypertension and Cognitive Dysfunction in a Pregnant Rat Model of PE; a Role for CD4+ T Cells.</ArticleTitle><Pagination><StartPage>e13935</StartPage><MedlinePgn>e13935</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/aji.13935</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Preeclampsia (PE) is associated with hypertension (HTN) during pregnancy and activated CD4+ T cells, inflammatory cytokines, and autoantibodies to the angiotensin II type I receptor (AT1-AA). Having had COVID-19 (CV) during pregnancy is associated with an increased incidence of a PE-like phenotype. Both PE and CV have long-lasting neurological implications and studies show that nonpregnant COVID patients produce AT1-AA. We have shown that CD4+ T cells from PE women cause a PE phenotype in nude athymic rats. In this study, we sought to examine the role of CD4+ T cells from PE with a CV History (Hx) to contribute to a PE phenotype and to determine the importance of CD4+ T cells in cognitive dysfunction during pregnancy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">At delivery, blood and placentas were collected, and one million placental CD4+ T cells from each PE and each normotensive patient, with (NT) or without (NP) a CV (Hx) during pregnancy, were isolated, purified, and injected i.p. into a gestational day (GD) 12 pregnant nude athymic rat (one patient/rat). At GD19, blood pressure (MAP) and circulating factors were assessed in recipient rats. Cognitive function and memory were assessed using Novel Object Recognition and Barnes Maze tests, respectively. Placental ACE-2 activity and AT1-AA were measured from COVID Hx patients. A one- or two-way ANOVA with Bonferroni's multiple comparisons test was used for statistical analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Blood pressure was increased in patients with PE, with or without COVID, compared to NT patients. There were no significant changes in placental ACE activity in patients with COVID Hx with or without PE. AT1-AA was elevated in PE patients and in both PE and NT COVID Hx compared to control NP. In pregnant recipient rats, MAP increased in CV Hx PE (113 ± 2, n = 8) compared to CV Hx NT (101 ± 5, n = 6). PE and PE CV Hx CD4+ T Cell recipient rats exhibited impaired memory and cognitive dysfunction (p &lt; 0.05), compared to control groups. Recipient rats of PE CV Hx CD4+ T cells had elevated AT1-AA compared to NT CV Hx recipients. Both COVID Hx groups and recipients of PE CD4+ T cells had elevated TNF alpha compared to NP.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings indicate that pregnant patients with a Hx of COVID during pregnancy produce AT1-AA, with or without PE. Recipients of CD4+ T cells from PE with or without a CV Hx during pregnancy cause HTN and elevated AT1-AA. TNF-α is elevated in PE and in CV Hx NT and PE recipients. Interestingly, recipients of T cells from PE patients with or without a Hx of CV had worse cognitive function during pregnancy, compared to recipient rats of NP CD4+ T cells. These data demonstrate the importance of CD4+ T cells in HTN and impaired neurological function during PE in the presence or absence of a prior COVID-19 infection during pregnancy.</AbstractText><CopyrightInformation>© 2024 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deer</LastName><ForeName>Evangeline</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrock</LastName><ForeName>Owen</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amaral</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7581-9182</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Baoying</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Rachael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Kedra</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleveland</LastName><ForeName>ELizabeth Hawthorne</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belk</LastName><ForeName>Sheila</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodd</LastName><ForeName>Cameronne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LaMarca</LastName><ForeName>Babbette</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-3340-6088</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology &amp; Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, Mississippi, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RO1HD067541</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31HD110230</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20GM121334</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL143459</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL151407</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RO1HL170622</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>19CDA34670055</GrantID><Agency>American Heart Association</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Am J Reprod Immunol</MedlineTA><NlmUniqueID>8912860</NlmUniqueID><ISSNLinking>1046-7408</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="Y">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011225" MajorTopicYN="Y">Pre-Eclampsia</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011923" MajorTopicYN="Y">Rats, Nude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010920" MajorTopicYN="N">Placenta</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">T cells</Keyword><Keyword MajorTopicYN="N">cognitive dysfunction</Keyword><Keyword MajorTopicYN="N">preeclampsia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39427297</ArticleId><ArticleId IdType="doi">10.1111/aji.13935</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>A. Agrawal and N. K. Wenger, “Hypertension During Pregnancy,” Current Hypertension Reports 22 (2020): 1–9.</Citation></Reference><Reference><Citation>B. LaMarca, D. C. Cornelius, A. C. Harmon, et al., “Identifying Immune Mechanisms Mediating the Hypertension During Preeclampsia,” American Journal of Physiology‐Regulatory, Integrative and Comparative Physiology 311, no. 1 (2016): R1–R9.</Citation></Reference><Reference><Citation>E. Deer, O. Herrock, N. Campbell, et al., “The Role of Immune Cells and Mediators in Preeclampsia,” Nature Reviews Nephrology 19, no. 4 (2023): 257–270.</Citation></Reference><Reference><Citation>A. C. Harmon, D. C. Cornelius, L. M. Amaral, et al., “The Role of Inflammation in the Pathology of Preeclampsia,” Clinical Science 130, no. 6 (2016): 409–419.</Citation></Reference><Reference><Citation>D. C. Cornelius, J. Cottrell, L. M. Amaral, and B. LaMarca, “Inflammatory Mediators: A Causal Link to Hypertension During Preeclampsia,” British Journal of Pharmacology 176, no. 12 (2019): 1914–1921.</Citation></Reference><Reference><Citation>A. C. Zenclussen, S. Fest, R. Joachim, B. F. Klapp, and P. C. Arck, “Introducing a Mouse Model for Pre‐Eclampsia: Adoptive Transfer of Activated Th1 Cells Leads to Pre‐Eclampsia‐Like Symptoms Exclusively in Pregnant Mice,” European Journal of Immunology 34, no. 2 (2004): 377–387.</Citation></Reference><Reference><Citation>K. Wallace, S. Richards, P. Dhillon, et al., “CD4+ T‐Helper Cells Stimulated in Response to Placental Ischemia Mediate Hypertension During Pregnancy,” Hypertension 57, no. 5 (2011): 949–955.</Citation></Reference><Reference><Citation>E. Deer, K. E. Reeve, L. Amaral, et al., “CD4+ T Cells Cause Renal and Placental Mitochondrial Oxidative Stress as Mechanisms of Hypertension in Response to Placental Ischemia,” American Journal of Physiology 320, no. 1 (2021): F47–F54.</Citation></Reference><Reference><Citation>K. E. Reeve, E. Deer, L. M. Amaral, et al., “Placental CD4+ T Cells From Preeclamptic Patients Cause Autoantibodies to the Angiotensin II Type I Receptor and Hypertension in a Pregnant Rat Model of Preeclampsia,” Exploration of Medicine 3, no. 1 (2022): 99.</Citation></Reference><Reference><Citation>D. C. Cornelius, J. Castillo, J. Porter, et al., “Blockade of CD40 Ligand for Intercellular Communication Reduces Hypertension, Placental Oxidative Stress, and AT1‐AA in Response to Adoptive Transfer of CD4+ T Lymphocytes From RUPP Rats,” American Journal of Physiology‐Regulatory, Integrative and Comparative Physiology 309, no. 10 (2015): R1243–R1250.</Citation></Reference><Reference><Citation>A. C. Harmon, T. Ibrahim, D. C. Cornelius, et al., “Placental CD4+ T Cells Isolated From Preeclamptic Women Cause Preeclampsia‐Like Symptoms in Pregnant Nude‐Athymic Rats,” Pregnancy Hypertension 15 (2019): 7–11.</Citation></Reference><Reference><Citation>A. Khalil, A. Samara, T. Chowdhury, and P. O'Brien, “Does COVID‐19 Cause Pre‐Eclampsia?,” Ultrasound in Obstetrics &amp; Gynecology 59, no. 2 (2022): 146–152.</Citation></Reference><Reference><Citation>R. Gholami, N. Borumandnia, E. Kalhori, M. Taheri, and N. Khodakarami, “The Impact of Covid‐19 Pandemic on Pregnancy Outcome,” BMC Pregnancy and Childbirth 23, no. 1 (2023): 811.</Citation></Reference><Reference><Citation>M. Mendoza, I. Garcia‐Ruiz, N. Maiz, et al., “Pre‐Eclampsia‐Like Syndrome Induced by Severe COVID‐19: A Prospective Observational Study,” BJOG: An International Journal of Obstetrics &amp; Gynaecology 127, no. 11 (2020): 1374–1380.</Citation></Reference><Reference><Citation>R. L. Molina, T. C. Tsai, D. Dai, et al., “Comparison of Pregnancy and Birth Outcomes Before vs During the COVID‐19 Pandemic,” JAMA Network Open 5, no. 8 (2022): e2226531–e2226531.</Citation></Reference><Reference><Citation>J. Villar, S. Ariff, R. B. Gunier, et al., “Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID‐19 Infection: The INTERCOVID Multinational Cohort Study,” Obstetrical &amp; Gynecological Survey 77, no. 2 (2022): 80–82.</Citation></Reference><Reference><Citation>R. Morris, A. S. Z. Moustafa, W. Kassahun‐Yimer, et al., “COVID‐19 Not Hypertension or Diabetes Increases the Risk of Preeclampsia Among a High‐Risk Population,” International Journal of Environmental Research and Public Health 19, no. 24 (2022): 16631.</Citation></Reference><Reference><Citation>I. Gurol‐Urganci, J. E. Jardine, F. Carroll, et al., “Maternal and Perinatal Outcomes of Pregnant Women With SARS‐CoV‐2 Infection at the Time of Birth in England: National Cohort Study,” American Journal of Obstetrics and Gynecology 225, no. 5 (2021): 522.e1–522.e11.</Citation></Reference><Reference><Citation>J. W. Tavares‐Júnior, A. C. C. de Souza, J. W. P. Borges, et al., “COVID‐19 Associated Cognitive Impairment: A Systematic Review,” Cortex 152 (2022): 77–97.</Citation></Reference><Reference><Citation>Y. Wu, X. Xu, Z. Chen, et al., “Nervous System Involvement After Infection With COVID‐19 and Other Coronaviruses,” Brain, Behavior, and Immunity 87 (2020): 18–22.</Citation></Reference><Reference><Citation>L. Mao, H. Jin, M. Wang et al., “Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China,” JAMA Neurology 77, no. 6 (2020): 683–690.</Citation></Reference><Reference><Citation>F. Alemanno, E. Houdayer, A. Parma, et al., “COVID‐19 Cognitive Deficits After Respiratory Assistance in the Subacute Phase: A COVID‐Rehabilitation Unit Experience,” PLoS ONE 16, no. 2 (2021): e0246590.</Citation></Reference><Reference><Citation>H. Zhou, S. Lu, J. Chen, et al., “The Landscape of Cognitive Function in Recovered COVID‐19 Patients,” Journal of Psychiatric Research 129 (2020): 98–102.</Citation></Reference><Reference><Citation>E. C. Miller and S. Vollbracht, “Neurology of Preeclampsia and Related Disorders: An Update in Neuro‐Obstetrics,” Current Pain and Headache Reports 25, no. 6 (2021): 40.</Citation></Reference><Reference><Citation>N. Campbell, L. Strong, X. Fang, et al., “AT1‐AA Infusion During Pregnancy Impairs CBF Autoregulation Postpartum,” International Journal of Cerebrovascular Disease and Stroke 6 (2023): 154.</Citation></Reference><Reference><Citation>J. P. Warrington, F. Fan, J. Duncan, et al., “The Angiotensin II Type I Receptor Contributes to Impaired Cerebral Blood Flow Autoregulation Caused by Placental Ischemia in Pregnant Rats,” Biology of Sex Differences 10, no. 1 (2019): 1–8.</Citation></Reference><Reference><Citation>J. P. Warrington, H. A. Drummond, J. P. Granger, and M. J. Ryan, “Placental Ischemia‐Induced Increases in Brain Water Content and Cerebrovascular Permeability: Role of TNF‐α,” American Journal of Physiology‐Regulatory, Integrative and Comparative Physiology 309, no. 11 (2015): R1425–R1431.</Citation></Reference><Reference><Citation>A. I. Rodriguez‐Perez, C. M. Labandeira, M. A. Pedrosa, et al., “Autoantibodies Against ACE2 and Angiotensin Type‐1 Receptors Increase Severity of COVID‐19,” Journal of Autoimmunity 122 (2021): 102683.</Citation></Reference><Reference><Citation>D. M. Del Valle, S. Kim‐Schulze, H. H. Huang, et al., “An Inflammatory Cytokine Signature Predicts COVID‐19 Severity and Survival,” Nature Medicine 26, no. 10 (2020): 1636–1643.</Citation></Reference><Reference><Citation>V. D. Garovic, R. Dechend, T. Easterling, et al., “Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association,” Hypertension 79, no. 2 (2022): e21–e41.</Citation></Reference><Reference><Citation>K. Reeve, E. Deer, L. M. Amaral, et al., “Placental CD4 (+) T Cells From Preeclamptic Patients Cause Autoantibodies to the Angiotensin II Type I Receptor and Hypertension in a Pregnant Rat Model of Preeclampsia,” Exploration of Medicine 3 (2022): 99–111.</Citation></Reference><Reference><Citation>G. W. Booz and K. M. Baker, “Role of Type 1 and Type 2 Angiotensin Receptors in Angiotensin II–Induced Cardiomyocyte Hypertrophy,” Hypertension 28, no. 4 (1996): 635–640.</Citation></Reference><Reference><Citation>American College of Obstetricians and Gynecologists Task Force on Hypertension in Pregnancy, “Hypertension in Pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy,” Obstetrics and Gynecology 122, no. 5 (2013): 1122–1131.</Citation></Reference><Reference><Citation>E. C. Miller and S. Vollbracht, “Neurology of Preeclampsia and Related Disorders: An Update in Neuro‐Obstetrics,” Current Pain and Headache Reports 25 (2021): 1–12.</Citation></Reference><Reference><Citation>J. P. Warrington, F. Fan, J. Duncan, et al., “The Angiotensin II Type I Receptor Contributes to Impaired Cerebral Blood Flow Autoregulation Caused by Placental Ischemia in Pregnant Rats,” Biology of Sex Differences 10 (2019): 1–8.</Citation></Reference><Reference><Citation>R. F. Damiano, B. F. Guedes, C. C. de Rocca, et al., “Cognitive Decline Following Acute Viral Infections: Literature Review and Projections for Post‐COVID‐19,” European Archives of Psychiatry and Clinical Neuroscience 272, no. 1 (2022): 139–154.</Citation></Reference><Reference><Citation>P. A. Sampaio Rocha‐Filho, P. M. Albuquerque, L. Carvalho, M. Dandara Pereira Gama, and J. E. Magalhães, “Headache, Anosmia, Ageusia and Other Neurological Symptoms in COVID‐19: A Cross‐Sectional Study,” Journal of Headache and Pain 23, no. 1 (2022): 2.</Citation></Reference><Reference><Citation>D. Bougakov, K. Podell, and E. Goldberg, “Multiple Neuroinvasive Pathways in COVID‐19,” Molecular Neurobiology 58, no. 2 (2021): 564–575.</Citation></Reference><Reference><Citation>M. Baracy Jr, F. Afzal, S. M. Szpunar, et al., “Coronavirus Disease 2019 (COVID‐19) and the Risk of Hypertensive Disorders of Pregnancy: A Retrospective Cohort Study,” Hypertension in Pregnancy 40, no. 3 (2021): 226–235.</Citation></Reference><Reference><Citation>F. Kalantar, S. Rajaei, A. B. Heidari, et al., “Serum Levels of Tumor Necrosis Factor‐α, Interleukin‐15 and Interleukin‐10 in Patients With Pre‐Eclampsia in Comparison With Normotensive Pregnant Women,” Iranian Journal of Nursing and Midwifery Research 18, no. 6 (2013): 463.</Citation></Reference><Reference><Citation>F. Silhol, G. Sarlon, J. C. Deharo, and B. Vaïsse, “Downregulation of ACE2 Induces Overstimulation of the Renin–Angiotensin System in COVID‐19: Should We Block the Renin–Angiotensin System?,” Hypertension Research 43, no. 8 (2020): 854–856.</Citation></Reference><Reference><Citation>L. Bao, W. Deng, B. Huang, et al., “The Pathogenicity of SARS‐CoV‐2 in hACE2 Transgenic Mice,” Nature 583, no. 7818 (2020): 830–833.</Citation></Reference><Reference><Citation>J. W. Duncan, D. Azubuike, G. W. Booz, et al., “Angiotensin II Type 1 Receptor Autoantibody Blockade Improves Cerebral Blood Flow Autoregulation and Hypertension in a Preclinical Model of Preeclampsia,” Hypertension in Pregnancy 39, no. 4 (2020): 451–460.</Citation></Reference><Reference><Citation>F. L. Fontes‐Dantas, G. G. Fernandes, E. G. Gutman, et al., “SARS‐CoV‐2 Spike Protein Induces TLR4‐Mediated Long‐Term Cognitive Dysfunction Recapitulating Post‐COVID‐19 Syndrome in Mice,” Cell Reports 42, no. 3 (2023): 112189.</Citation></Reference><Reference><Citation>F. Fatmawati and S. Mulyanti, “Risk Factors Associated With the Severity of COVID‐19,” Malaysian Journal of Medical Sciences: MJMS 30, no. 3 (2023): 84.</Citation></Reference><Reference><Citation>S. J. Yong, “Long COVID or Post‐COVID‐19 Syndrome: Putative Pathophysiology, Risk Factors, and Treatments,” Infectious Diseases 53, no. 10 (2021): 737–754.</Citation></Reference><Reference><Citation>K. Melchiorre, R. Sharma, and B. Thilaganathan, “Cardiovascular Implications in Preeclampsia: An Overview,” Circulation 130, no. 8 (2014): 703–714.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>